In short
Clinical trials of Abt-494 are studying its use in adults with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis. The trials aim to assess how well it works, how safe it is, and how well people tolerate it. They focus on adults with active disease, including some who did not respond to biologic DMARDs.
Key points
- Clinical trials of Abt-494 are studying adults with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis. The main trial listed is a Phase 3 study with 690 participants. It compares Abt-494 with placebo to see whether it improves signs and symptoms of active disease. The trial also looks at safety and tolerability. The main outcome is ASAS 40 response at week 14, a standard measure of improvement in this condition.
Clinical trial overview
The main study of Abt-494 in the provided data is NCT04169373, a Phase 3 interventional trial in adults with axial spondyloarthritis.
This trial was completed and enrolled 690 people.
The study looked at adults with active disease, including people with ankylosing spondylitis who had an inadequate response to biologic DMARDs in one study group, and people with non-radiographic axial spondyloarthritis in another study group.
Study design and who was included
The trial compared Abt-494 15 mg taken by mouth with a matching placebo, which is a look-alike treatment with no active study medicine.
This kind of design helps researchers see whether any improvement is more likely due to the study medicine and not to chance.
The trial focused on adults with active axial spondyloarthritis, so the people in the study were not healthy volunteers; they had ongoing symptoms and inflammation from this disease.
One part of the study included subjects with active ankylosing spondylitis who had not responded well enough to biologic DMARDs, often called bDMARD-IR.
The other part included subjects with active non-radiographic axial spondyloarthritis.
What the trial measured
The main endpoint, or main result the study wanted to measure, was ASAS 40 response at week 14 in both study groups.
ASAS 40 is a standard measure in axial spondyloarthritis research. It means a 40% improvement in signs and symptoms based on a set of clinical questions and assessments.
The trial also assessed safety and tolerability, which means whether the treatment caused problems and how well people could take it during the study.
These outcomes matter because patients and researchers need to know both whether a treatment works and whether it can be used safely in the study setting.
What the trial results mean for patients
This study was designed to answer a practical question: can Abt-494 reduce symptoms and improve disease activity in adults with active axial spondyloarthritis better than placebo?
Because the trial included both ankylosing spondylitis and non-radiographic axial spondyloarthritis, it covered two important patient groups within the same disease family.
The week 14 endpoint shows that the researchers looked for relatively early improvement after treatment started.
Since the study was completed, it adds to the evidence about how Abt-494 performs in a larger group of adults with this inflammatory spine disease.